Proapoptotic effects of new pentabromobenzylisothiouronium salts in a human prostate adenocarcinoma cell line
Mirosława Koronkiewicz1, Zygmunt Kazimierczuk, Kinga Szarpak
1Department of Cell Biology, National Medicines Institute, Warszawa, Poland. koronkiewicz@il.waw.pl
Abstract:
Prostate cancer is the second most common cancer in elderly men worldwide and its incidence rate is rising continuously. Agents capable of inducing apoptosis in prostate cancer cells seem a promising approach to treat this malignancy. In this study we describe the synthesis of a number of novel N- and N,N'-substituted S-2,3,4,5,6-pentabromobenzylisothiouronium bromides and their activity against the human prostate adenocarcinoma PC3 cell line. All the compounds produced changes in mitochondrial transmembrane potential and cell cycle progression, showed a cytostatic effect and induced apoptosis in the tested cancer line in a concentration- and time-dependent manner. The most effective compounds ZKK-3, ZKK-9 and ZKK-13 produced, at 20 microM concentration, apoptosis in 42, 46, and 66% of the cells, respectively, after 48 h incubation. Two selected S-2,3,4,5,6-pentabromobenzylisothiouronium bromides (ZKK-3, ZKK-9) showed also a synergic proapoptotic effect with the new casein kinase II inhibitor 2-(4-methylpiperazin-1-yl)-4,5,6,7-tetrabromo-1H-benzimidazole (TBIPIP) in the PC3 cell line.
Insights
Novel isothiouronium bromides effectively induce apoptosis in prostate cancer cells. These compounds show promise for developing new prostate cancer treatments by targeting cell death pathways.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Prostate cancer is a leading cancer in elderly men globally, with increasing incidence.
- Inducing apoptosis (programmed cell death) in cancer cells is a key therapeutic strategy.
- Novel chemical agents are needed to combat prostate adenocarcinoma.
Purpose of the Study:
- To synthesize and evaluate novel N- and N,N'-substituted S-2,3,4,5,6-pentabromobenzylisothiouronium bromides.
- To assess the anti-cancer activity of these compounds against the PC3 human prostate adenocarcinoma cell line.
- To investigate their mechanism of action, including effects on mitochondrial potential and cell cycle.
Main Methods:
- Synthesis of novel isothiouronium bromide derivatives.
- In vitro testing against PC3 prostate cancer cells.
- Analysis of mitochondrial transmembrane potential and cell cycle progression.
- Concentration- and time-dependent apoptosis assays.
Main Results:
- All synthesized compounds altered mitochondrial potential and cell cycle, exhibiting cytostatic effects.
- Compounds induced apoptosis in PC3 cells in a dose- and time-dependent manner.
- ZKK-3, ZKK-9, and ZKK-13 demonstrated significant apoptosis induction (42-66% at 20 microM after 48h).
- ZKK-3 and ZKK-9 showed synergistic proapoptotic effects with casein kinase II inhibitor TBIPIP.
Conclusions:
- Novel S-2,3,4,5,6-pentabromobenzylisothiouronium bromides are potent inducers of apoptosis in prostate cancer cells.
- These compounds represent promising candidates for the development of new prostate cancer therapies.
- Synergistic effects with other agents like TBIPIP warrant further investigation for combination therapies.
